Nothing Special   »   [go: up one dir, main page]

CA2406755A1 - Systeme et procede de therapie genique utilisant alpha-msh et ses derives - Google Patents

Systeme et procede de therapie genique utilisant alpha-msh et ses derives Download PDF

Info

Publication number
CA2406755A1
CA2406755A1 CA002406755A CA2406755A CA2406755A1 CA 2406755 A1 CA2406755 A1 CA 2406755A1 CA 002406755 A CA002406755 A CA 002406755A CA 2406755 A CA2406755 A CA 2406755A CA 2406755 A1 CA2406755 A1 CA 2406755A1
Authority
CA
Canada
Prior art keywords
msh
gene therapy
derivatives
gene
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002406755A
Other languages
English (en)
Inventor
Anna P. Catania
James M. Lipton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Zengen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zengen Inc filed Critical Zengen Inc
Publication of CA2406755A1 publication Critical patent/CA2406755A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

L'invention concerne l'utilisation de alpha-MSH et/ou ses dérivés comme appoint à une thérapie génique. Dans un mode de réalisation, le vecteur de thérapie génique comprend des acides nucléiques qui expriment alpha-MSH et/ou ses dérivés. Un promoteur génique de réponse immune ou inflammatoire peut réguler l'expression de alpha-MSH et/ou de ses dérivés. Les séquences peuvent également être exprimées en même temps qu'un gène thérapeutique utilisant une séquence de site d'entrée ribosomique interne. Dans un autre mode de réalisation, une dose pharmacologiquement efficace de alpha-MSH et/ou de ses dérivés peut être administrée avant, après ou en même temps que le vecteur de thérapie génique transportant le gène approprié.
CA002406755A 2000-04-28 2001-04-27 Systeme et procede de therapie genique utilisant alpha-msh et ses derives Abandoned CA2406755A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20028700P 2000-04-28 2000-04-28
US60/200,287 2000-04-28
PCT/US2001/013826 WO2001082699A1 (fr) 2000-04-28 2001-04-27 Systeme et procede de therapie genique utilisant alpha-msh et ses derives

Publications (1)

Publication Number Publication Date
CA2406755A1 true CA2406755A1 (fr) 2001-11-08

Family

ID=22741073

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002406755A Abandoned CA2406755A1 (fr) 2000-04-28 2001-04-27 Systeme et procede de therapie genique utilisant alpha-msh et ses derives

Country Status (6)

Country Link
EP (1) EP1280409A4 (fr)
JP (1) JP2004509065A (fr)
CN (1) CN1429073A (fr)
AU (1) AU2001257420A1 (fr)
CA (1) CA2406755A1 (fr)
WO (1) WO2001082699A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106905432B (zh) * 2015-12-18 2018-12-21 兰州大学 一种α促黑素细胞激素的融合蛋白及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532347A (en) * 1992-04-10 1996-07-02 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non-Profit Organization DNA encoding α melanocyte stimulating hormone receptor
US5744304A (en) * 1995-05-30 1998-04-28 Board Of Regents, The University Of Texas System Inflammation-induced expression of a recombinant gene
CA2272820C (fr) * 1996-11-20 2012-09-11 Introgen Therapeutics, Inc. Procede ameliore pour production et purification de vecteurs d'adenovirus
AU3117600A (en) * 1998-12-09 2000-06-26 Eleanor Roosevelt Institute Composition and method for regulation of body weight and associated conditions
JP2002534968A (ja) * 1999-01-22 2002-10-22 ザ スキーペンズ アイ リサーチ インスティテュート インコーポレイテッド α−メラニン細胞刺激ホルモンによる調節Ｔ細胞の活性化
EP1303625A2 (fr) * 2000-07-14 2003-04-23 Zycos Inc. Composes en rapport avec alpha-msh et methodes d'utilisation

Also Published As

Publication number Publication date
JP2004509065A (ja) 2004-03-25
CN1429073A (zh) 2003-07-09
EP1280409A4 (fr) 2004-05-19
EP1280409A1 (fr) 2003-02-05
AU2001257420A1 (en) 2001-11-12
WO2001082699A1 (fr) 2001-11-08

Similar Documents

Publication Publication Date Title
EP3453401A1 (fr) Combinaison d'interleukine et utilisation de celle-ci
ES2690147T3 (es) Apelina pegilada y usos de la misma
CN105008395B (zh) 长效单链胰岛素类似物
ES2712805T3 (es) Productos farmacéuticos antiinflamatorios
EP2519250A1 (fr) Analogues d'interférons
CA2692358A1 (fr) Proteines de type interferon humain recombinant
CA2748392C (fr) Prevention et/ou traitement du syndrome de defaillance multiviscerale avec de l'interleukine 22
CN111040021B (zh) 一种改善生物活性蛋白性质的载体蛋白
JP2016508517A (ja) インスリン分泌性ポリペプチド
CA2406755A1 (fr) Systeme et procede de therapie genique utilisant alpha-msh et ses derives
US20040110696A1 (en) Gene therapy system and method using alpha-msh and its derivatives
EP3385285B1 (fr) Protéine de fusion pour l'hormone qu'est l'alpha-mélanostimuline, son procédé de préparation et son utilisation
US11633456B2 (en) Compositions and methods for promoting hair growth
JP2019511567A5 (fr)
US20030108523A1 (en) Cancer treatment system
EA038673B1 (ru) Плазмидная днк, кодирующая дефенсин hnp-1, либо hnp-2, либо hnp-3
AU2011305386B2 (en) Formulations for bovine Granulocyte Colony Stimulating Factor and variants thereof
US5440022A (en) Hepatokine and methods for its use
US20230322872A1 (en) Recombinant protein comprising multiple multi-peptide sets, pharmaceutical composition comprising the recombinant protein, and method for preparing the recombinant protein
WO2024110757A1 (fr) Commande d'auto-assemblage de nanocage
CN102327242B (zh) 一种聚乙二醇-集成干扰素变异体冻干制剂
WO2023038497A1 (fr) Peptide présentant une efficacité d'administration de médicament transdermique améliorée et une activité lipolytique
WO2007037514A1 (fr) Application innovante d'un facteur de croissance similaire au facteur de croissance épidermique de liaison à l'héparine dans un but médical
KR20240035722A (ko) 세포 내 형질주입을 위한 신규한 폴리펩타이드 조성물
KR20020007382A (ko) 공유결합으로 올리고머화된 막 파괴성 펩티드

Legal Events

Date Code Title Description
FZDE Dead